Back to top

Analyst Blog

As a boost to its efforts to expand its coronary business globally, Medtronic Inc. (MDT - Analyst Report) received CE Mark (Conformité Européenne) in Europe and Therapeutic Goods Administration (TGA) listing in Australia for two of its Symplicity line of products.

According to the company, during renal denervation procedures for patients with uncontrolled hypertension, these two systems, viz. 4 Fr multi-electrode Symplicity Spyral catheter and Symplicity G3 radio frequency (RF) generator, are expected to substantially reduce ablation time and provide ease of deliverability.

Uncontrolled hypertension is directly linked with a high risk of heart attacks, stroke, heart failure, kidney disease and even death. Under traditional therapy, patients are prescribed with 3-5 classes of anti-hypertensive medications that can have a number of side effects.

Given almost 120 million high blood pressure patients worldwide suffering from uncontrolled hypertension, with systolic blood pressures at or above 140 mm Hg, we remain confident about the global market adoption of this new system, given that it hardly has any side effect.

In renal denervation, Medtronic is currently investing in developing referral networks, reimbursement, technology development, and clinical and economic evidence to further strengthen its leadership position and grasp the long-term opportunity in hypertension treatment.

Currently, the company is perusing research and development in renal denervation worldwide and has many ongoing clinical studies. Last month, the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) allowing Medtronic to initiate SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in patients in the U.S. This is presently available only for investigational use in the country.

The study will evaluate the Symplicity renal denervation system in patients with moderate uncontrolled hypertension (systolic blood pressure greater than or equal to 140 and less than 160 mm Hg, despite being administered to treatment with three or more anti-hypertensive medications of different classes).

Moreover, the Symplicity HTN-3 U.S. pivotal study – the first and only pivotal U.S. clinical trial of the Symplicity renal denervation system for uncontrolled hypertension, completed enrollment of 535 patients across nearly 90 U.S. medical centers in May 2013.  The results are expected to be available during the first half of 2014. 

Currently, Medtronic carries a Zacks Rank #3 (Hold). Better-ranked medical device stocks such as Hill-Rom Holdings, Inc. (HRC - Snapshot Report), Natus Medical Inc. (BABY - Snapshot Report) and NuVasive, Inc. (NUVA - Snapshot Report) are also expected to do well. While Hill-Rom and Natus Medical sports a Zacks Rank #1 (Strong Buy), NuVasive holds a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CTPARTNERS… CTP 13.33 +3.49%
SAIA INC SAIA 45.65 +1.00%
VASCO DATA… VDSI 13.57 +0.67%
AMEDISYS IN… AMED 20.18 +0.10%
FIRSTSERVIC… FSRV 55.66 -0.13%